Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KPNA7 siRNA
- Development stage
- Preclinical
- Lead developer
- Institute of Biomedical Technology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
KPNA7 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Karyopherin Alpha 7 (KPNA7), a member of the alpha karyopherin family of nuclear import receptors. KPNA7 is frequently overexpressed in pancreatic cancer and is absent in most normal adult tissues, making it a selective therapeutic target. By inhibiting KPNA7 expression, this siRNA induces G1 cell cycle arrest through the upregulation of the cell cycle regulator p21. In preclinical models of pancreatic cancer, KPNA7 silencing has been shown to significantly reduce cell growth, anchorage-independent growth, migration, and invasion, suggesting its potential as a targeted antineoplastic agent.
- Other names
- siRNA targeting KPNA7KPNA7-silencing siRNAKPNA-7-silencing siRNAKPNA 7-silencing siRNA
02
Targets
AGO2 (Argonaute RISC catalytic component 2)KPNA (Karyopherin alpha family)
Beyond the preview
Go deeper on KPNA7 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KPNA7 siRNA.